NGM Bio hinted at financial strain at the end of February when it announced 2022 financial results, noting a narrowed focus on oncology and an intention to partner out some of the other programs in a cash-saving move.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of industry veteran Mark Velleca, M.D., Ph.D. as Chief Executive Officer and a member of its Board of Directors. Mark succeeds Sapan Shah, Ph.D., who is leaving StrideBio to pursue other opportunities after having served as Chief Executive Officer for the past three years.
StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the expansion of its leadership team with the appointments of Ariane Hamaide, as Vice President, Strategy and Operations, Mike Havert, Ph.D., as Vice President, Regulatory Affairs, Sandra Lueken, as Vice President, Quality Operations, and Jodi Wolff, Ph.D., M.S.S.W., as Vice President, Patient Engagement & Advocacy.
RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures, along with existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments. In conjunction with the financing, Shaan C. Gandhi, M.D., D.Phil., Director at Northpond Ventures, and Karen Hong, Ph.D., Partner at Novo Ventures, an affiliate of Novo Holdings A/S, have joined the company's Board of Directors.
Strides Pharma's Generic PREDNISONE Receives Approval In The US
Sarepta Therapeutics is paying privately-held StrideBio $48 million to develop gene therapies for at least four central nervous system conditions, potentially adding to a beefy pipeline of candidates for genetically driven rare diseases.